IMT Header
  • IMT Header 2

Cambridge Healthtech Institute is pleased to bring you the Tenth Annual ImVacS: Immunotherapy and Vaccine Summit. From its beginnings as a lone adjuvants conference, ImVacS has grown to a multi-track event spanning vaccines, immunotherapies, and platform technologies. This year's event has been expanded to five days with coverage on adjuvants, vaccine and immunotherapy technologies, immunomodulatory therapeutic antibodies for cancer, combination cancer immunotherapy, and T cell target discovery. ImVacS 2015 promises to be a must-attend event for commercial and academic entities to continue advancing immunotherapies and vaccines through technology and innovation.

WHAT'S NEW THIS YEAR? 

  • A new plenary keynote session will bring together 300 conference attendees in one session
  • Expanded coverage on T cell target discovery with an emphasis on CAR T cells
  • An additional conference track, Platform Technologies for Immune-Based Therapy, has been added
  • The latest developments in vaccine adjuvants for emerging infectious diseases will be presented
  • A new conference, Rational Combination Cancer Immunotherapy, will explore the strategies driving specific types of immunotherapy combinations and look at next generation tools

Conference Tracks


 
 
 
 
 
 
 

 

 
 
 
 
 
 

 

 

Each year, ImVacS brings vaccine professionals together from around the world to discuss the crucial issues surrounding vaccine development. Along with presenting a snapshot of where vaccines stand today, the meeting also provides an important venue for networking, information exchange, and establishing collaborations.

The “Novel Vaccines” meeting explores how vaccine development is being innovated in order to create more efficacious vaccines, such as using Systems Biology or Reverse Vaccinology. The use of adjuvants – their safety and mode of action – will also be discussed, as will DNA vaccines, Toll-Like Receptors, and novel modes of delivery. In addition, how improved vaccines are targeting infectious diseases will be addressed and updated.